MD970134A - Compozitie farmaceutica de aerosol, procedeu de preparare a ei, metoda de tratament al afectiunilor respiratorii, substanta tensioactiva pentru astfel de compozitii si procedeu de obtinere a Compozitie farmaceutica de aerosol, ce contine medicament pulverulent, propelent de fluorura de carbon sau clorfluorura de carbon cu continut de hidrogen si substanta tensioactiva cu formula <CHFORM> in care n reprezinta un numar intreg de la 1 pina la 18m reprezinta un numar intreg de la 0 pina la 17; si R1, R2 si R3 fiecare independent reprezinta un atom de hidrogen sau o grupa C1-4alchil. Revendicari: 20 - Google Patents

Compozitie farmaceutica de aerosol, procedeu de preparare a ei, metoda de tratament al afectiunilor respiratorii, substanta tensioactiva pentru astfel de compozitii si procedeu de obtinere a Compozitie farmaceutica de aerosol, ce contine medicament pulverulent, propelent de fluorura de carbon sau clorfluorura de carbon cu continut de hidrogen si substanta tensioactiva cu formula <CHFORM> in care n reprezinta un numar intreg de la 1 pina la 18m reprezinta un numar intreg de la 0 pina la 17; si R1, R2 si R3 fiecare independent reprezinta un atom de hidrogen sau o grupa C1-4alchil. Revendicari: 20

Info

Publication number
MD970134A
MD970134A MD97-0134A MD970134A MD970134A MD 970134 A MD970134 A MD 970134A MD 970134 A MD970134 A MD 970134A MD 970134 A MD970134 A MD 970134A
Authority
MD
Moldova
Prior art keywords
surfactant
integer
aerosol formulation
pharmaceutical aerosol
hydrogen
Prior art date
Application number
MD97-0134A
Other languages
English (en)
Other versions
MD1900C2 (ro
MD1900B2 (ro
Inventor
Li Ch Li-Bovet
Keith Arthur Johnson
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of MD970134A publication Critical patent/MD970134A/ro
Publication of MD1900B2 publication Critical patent/MD1900B2/ro
Publication of MD1900C2 publication Critical patent/MD1900C2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MD97-0134A 1994-09-28 1995-09-27 Compoziţie farmaceutică de aerosol şi metodă de tratament al afecţiunilor respiratorii MD1900C2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9419536A GB9419536D0 (en) 1994-09-28 1994-09-28 Medicaments
PCT/IB1995/000866 WO1996009816A1 (en) 1994-09-28 1995-09-27 Medicaments

Publications (3)

Publication Number Publication Date
MD970134A true MD970134A (ro) 1999-02-28
MD1900B2 MD1900B2 (ro) 2002-04-30
MD1900C2 MD1900C2 (ro) 2002-12-31

Family

ID=10762008

Family Applications (1)

Application Number Title Priority Date Filing Date
MD97-0134A MD1900C2 (ro) 1994-09-28 1995-09-27 Compoziţie farmaceutică de aerosol şi metodă de tratament al afecţiunilor respiratorii

Country Status (32)

Country Link
US (1) US5849265A (ro)
EP (1) EP0783302B1 (ro)
JP (1) JPH10506887A (ro)
KR (1) KR100375469B1 (ro)
CN (1) CN1084614C (ro)
AP (1) AP742A (ro)
AT (1) ATE187063T1 (ro)
AU (1) AU707922B2 (ro)
BG (1) BG62839B1 (ro)
BR (1) BR9509108A (ro)
CZ (1) CZ286356B6 (ro)
DE (1) DE69513671T2 (ro)
DK (1) DK0783302T3 (ro)
EE (1) EE03380B1 (ro)
ES (1) ES2140706T3 (ro)
FI (1) FI971279A (ro)
GB (1) GB9419536D0 (ro)
GE (1) GEP20002140B (ro)
GR (1) GR3032245T3 (ro)
HU (1) HU221856B1 (ro)
IS (1) IS1991B (ro)
MD (1) MD1900C2 (ro)
MX (1) MX9702149A (ro)
NO (1) NO313658B1 (ro)
NZ (1) NZ292995A (ro)
OA (1) OA10603A (ro)
PL (1) PL181453B1 (ro)
RO (1) RO118564B1 (ro)
RU (1) RU2157188C2 (ro)
SK (1) SK281519B6 (ro)
UA (1) UA47412C2 (ro)
WO (1) WO1996009816A1 (ro)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
US6984404B1 (en) 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
JP2002541183A (ja) * 1999-04-14 2002-12-03 グラクソ グループ リミテッド 医薬用エアゾール製剤
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
US6451287B1 (en) 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
GB0016876D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
DZ3468A1 (fr) * 2000-08-05 2002-02-14 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyle) oxy!-11.beta.-hydroxy-16.alpha.-methyle-3-oxo-androst-1,4,-diene-17-acide carbothioique s-fluoromethyle ester utilise comme agent anti inflammatoire
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858593B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
JP2004509159A (ja) 2000-09-22 2004-03-25 グラクソ　グループ　リミテッド 新規なアルカン酸誘導体
GB0106046D0 (en) 2001-03-12 2001-05-02 Glaxo Group Ltd Canister
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
CN1302007C (zh) * 2001-04-30 2007-02-28 葛兰素集团有限公司 具有抗炎性的在17.α位上具有环酯基的雄甾烷的17.β.－硫代羧酸酯衍生物
ATE399174T1 (de) * 2001-06-12 2008-07-15 Glaxo Group Ltd Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen
GB0118364D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Compounds
MXPA04001049A (es) * 2001-08-03 2004-05-20 Glaxo Group Ltd Compuestos surfactantes y usos de los mismos.
GB0125127D0 (en) 2001-10-19 2001-12-12 Glaxo Group Ltd Compounds
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US7217833B2 (en) * 2002-02-13 2007-05-15 Glaxco Group Limited Carboxylic acid compounds for use as surfactants
GB0205327D0 (en) * 2002-03-06 2002-04-17 Glaxo Group Ltd compounds
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
CA2534985A1 (en) 2003-08-11 2005-02-24 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
WO2005023330A2 (en) 2003-08-29 2005-03-17 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
US7030255B2 (en) * 2004-03-09 2006-04-18 Lyondell Chemical Technology, L.P. Oxidation process with in-situ H202 generation and polymer-encapsulated catalysts therefor
EP1811981B1 (en) * 2004-10-12 2008-08-13 Merck Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
EP1949891A1 (en) 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
EP2120875B1 (en) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
JP2849471B2 (ja) * 1989-06-22 1999-01-20 アライアンス ファーマシューティカル コーポレイション 界面活性剤の性質を有するフッ素およびリン含有両親媒性分子
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
DE69133314D1 (de) * 1990-03-23 2003-10-23 Minnesota Mining & Mfg Aerosolzubereitungen zur dosierten Abgabe
WO1992000062A1 (en) * 1990-06-27 1992-01-09 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations

Also Published As

Publication number Publication date
US5849265A (en) 1998-12-15
KR970705981A (ko) 1997-11-03
BR9509108A (pt) 1998-07-14
SK281519B6 (sk) 2001-04-09
BG62839B1 (bg) 2000-09-29
NO313658B1 (no) 2002-11-11
NO971422D0 (no) 1997-03-25
MD1900C2 (ro) 2002-12-31
ATE187063T1 (de) 1999-12-15
GB9419536D0 (en) 1994-11-16
IS4438A (is) 1997-03-10
HU221856B1 (hu) 2003-02-28
CN1084614C (zh) 2002-05-15
EP0783302A1 (en) 1997-07-16
NZ292995A (en) 1998-10-28
OA10603A (en) 2002-08-30
MX9702149A (es) 1998-04-30
AU707922B2 (en) 1999-07-22
EE9700061A (et) 1997-08-15
EE03380B1 (et) 2001-04-16
CN1168630A (zh) 1997-12-24
KR100375469B1 (ko) 2003-10-17
HUT77377A (hu) 1998-04-28
IS1991B (is) 2005-02-15
AP742A (en) 1999-04-26
PL319342A1 (en) 1997-08-04
UA47412C2 (uk) 2002-07-15
FI971279A0 (fi) 1997-03-26
MD1900B2 (ro) 2002-04-30
CZ93697A3 (en) 1997-08-13
GR3032245T3 (en) 2000-04-27
WO1996009816A1 (en) 1996-04-04
DE69513671T2 (de) 2000-04-06
SK39397A3 (en) 1997-10-08
ES2140706T3 (es) 2000-03-01
BG101347A (en) 1997-12-30
GEP20002140B (en) 2000-06-25
RU2157188C2 (ru) 2000-10-10
AU3532195A (en) 1996-04-19
EP0783302B1 (en) 1999-12-01
JPH10506887A (ja) 1998-07-07
RO118564B1 (ro) 2003-07-30
DK0783302T3 (da) 2000-05-29
NO971422L (no) 1997-05-23
DE69513671D1 (de) 2000-01-05
FI971279A (fi) 1997-03-26
CZ286356B6 (cs) 2000-03-15
AP9700951A0 (en) 1997-04-30
PL181453B1 (pl) 2001-07-31

Similar Documents

Publication Publication Date Title
MD970134A (ro) Compozitie farmaceutica de aerosol, procedeu de preparare a ei, metoda de tratament al afectiunilor respiratorii, substanta tensioactiva pentru astfel de compozitii si procedeu de obtinere a Compozitie farmaceutica de aerosol, ce contine medicament pulverulent, propelent de fluorura de carbon sau clorfluorura de carbon cu continut de hidrogen si substanta tensioactiva cu formula &lt;CHFORM&gt; in care n reprezinta un numar intreg de la 1 pina la 18m reprezinta un numar intreg de la 0 pina la 17; si R1, R2 si R3 fiecare independent reprezinta un atom de hidrogen sau o grupa C1-4alchil. Revendicari: 20
AU4346996A (en) Pharmaceutical aerosol containing at least one sugar
CA2125665A1 (en) Medicaments
NZ240237A (en) An aerosol formulation (free of surfactant) for treatment of asthma comprising: a hydrofluorocarbon propellant, ethanol, and beclomethasone 17,21 dipropionate; preparation thereof
CA2402300A1 (en) Fluorocarbon aerosol medicaments
GB9616237D0 (en) Aerosol formulations
ES2084360T3 (es) Formulaciones de aerosoles exentas de clorofluorocarbonos.
PL336885A1 (en) Therapeutic products in the aerosol form
MY130946A (en) Medicinal inhalation aerosol formulations containing budesonide
IL153726A0 (en) Novel aerosol formulation containing a polar fluorinated molecule
HU9201258D0 (en) Process for the production of medical preparations for treating hiv infections and of their active agents
EP0652755A1 (en) THERAPEUTIC USE OF PHOSPHORYL-L-SERINE-N-ACYL-SPHINGOSINE.
WO1998003540A3 (en) 1,2-substituted cycloalkane derivatives as thrombine inhibitors, a process for the preparation thereof and the use thereof in pharmaceutical formulations
AU579295B2 (en) New thiazole derivatives, a process for the preparation thereof and pharmaceutical compositions containing them
CA2200986A1 (en) Medicaments
HUP9901348A2 (hu) Tumor elleni hatású 2-[2-[(2-hidroxi-etil)-amino]-etil]-5-[[2-(metil-amino)-etil]-amino]-indazolo[4,3-gh]izokinolin-6(2H)-on-származékok, előállításuk, intermedierek és e vegyületeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
PD99 Pending application
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees